Specialized division focused on research and product development for rare and ultra-rare diseases highlights Chiesi’s commitment to building a brighter future for patients Chiesi Global Rare Diseases unit will harness the full resources of Chiesi Group to support rare disease communities, with…
Chiesi Group expands distribution network via acquisition for worldwide product rights. Chiesi Group will establish offices in Toronto, Canada. PARMA, Italy, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group) and Apotex,…
Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), announces the closing of the licensing transaction with Santhera Pharmaceuticals. As per the agreement, Chiesi Group is in-licensing a product whose active principle is idebenone for the treatment of Leber’s…
Chiesi, an international research-focused healthcare Group (Chiesi Group) and Inhibrx, Inc. (“Inhibrx”), a clinical-stage biotechnology company developing a broad pipeline of novel biologic therapeutic candidates, announced today they entered into an agreement granting Chiesi Group an option to…
Chiesi Farmaceutici, an international research focused healthcare group (Chiesi Group) has entered into an exclusive license agreement with Santhera Pharmaceutical, under which Chiesi Group will in-license an orphan drug whose active principle is i debenone for the treatment of Leber hereditary…
Chiesi received the " Imprese per innovazione " award during the Connext event of February 6 and 7. Connext is the first National meeting of industry partnership organized by Confindustria, with the purpose of strengthening collaborations in the production area and in research and innovation…
TiumBio grants Chiesi global rights to develop small molecules targeting transforming growth factor beta (TGF-β) signaling in respiratory indications This agreement expands Chiesi’s comprehensive R&D program in respiratory diseases with high unmet medical need Parma (Italy)- December 21, 2018 -…
StartUp Health announced a successful fundraise of 31 million dollars for its Transformer Fund II from a prominent consortium of strategic partners, including, as previously announced in June, the Chiesi Group. Other partners in this fund include large healthcare organizations, multinational large…
Chiesi has signed a strategic deal with StartUp Health, a global health innovation company focused on achieving Health Moonshots. StartUp Health has the largest digital health-focused portfolio in the world, consisting of over 235 companies applying technology to solve key challenges such as…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
